Abeona Therapeutics (ABEO) Enterprise Value (2010 - 2026)

Abeona Therapeutics' Enterprise Value history runs 17 years deep, the most recent figure standing at -$168.3 million for Q1 2026.

• On a quarterly basis, Enterprise Value fell 99.95% year-over-year to -$168.3 million in Q1 2026; TTM through Mar 2026 was -$168.3 million, a 99.95% decrease from a year earlier, with the FY2025 full-year figure at -$191.4 million, down 95.19% from the prior year.
• Enterprise Value advanced to -$168.3 million in Q1 2026 per ABEO's latest filing, from -$191.4 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$16.9 million in Q1 2022 and bottomed at -$225.5 million in Q2 2025.
• The 5-year median for Enterprise Value is -$54.1 million (2023), against an average of -$88.6 million.
• Across the five-year window, Enterprise Value jumped 80.76% in 2022 and plunged 197.75% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$52.5 million in 2022, then fell by 0.15% to -$52.6 million in 2023, then tumbled by 86.55% to -$98.1 million in 2024, then sank by 95.19% to -$191.4 million in 2025, then advanced by 12.09% to -$168.3 million in 2026.
• Per Business Quant, the three latest ABEO Enterprise Value figures stand at -$168.3 million (Q1 2026), -$191.4 million (Q4 2025), and -$207.5 million (Q3 2025).